Skip to content

maternal pediatric pharmacology R21 eligibility Guide

Updated 8 official sources

Quick Answer: PAR-25-111 was an NIH R21 for maternal and pediatric pharmacology and therapeutics projects.

Full answer and how we checked it

It expired July 7, 2026, was clinical trial optional, capped at $275,000 in direct costs over two years, and useful for planning similar NICHD, NIAID, NIDA, or ORWH-aligned projects. The 2026 decision turns on 7 checks.

Who this is for: Maternal-fetal medicine teams, pediatric pharmacology groups, neonatal researchers, pharmacometric modelers, translational therapeutics teams, clinical trial offices, and sponsored-research teams deciding whether an R21 path fits.

Data note: This guide uses NIH PAR-25-111, companion NIH PAR-25-110, NOT-HD-26-003, Grants.gov listings 357185 and 363679, and NIH RePORTER award records checked on October 10, 2026.

In this guide

Quick Facts

Agency
HHS
Last deadline
Jul 6, 2026 (passed)
Status
Closed

Assistance Listing 93.855: all awards

Source: USASpending.gov FY2024

These figures cover all National Institutes of Health awards under Assistance Listing 93.855, of every award type. They are not figures for the award this guide describes, and one award of that kind can be far smaller.

Total Awards (FY2024, whole listing)
5,330
Avg Award (whole listing)
$2,808,443
Median Award (whole listing)
$1,224,444
Total Funding (FY2024, whole listing)
$4.1B
YoY Funding Trend
+1%

Data last verified: May 25, 2026

PAR-25-111 is not a broad child-health R21. NIH frames the route around translational and clinical research that improves safe and effective precision therapeutics for pregnant women, lactating women, fetuses, neonates, children, and adolescents, including people with disabilities.

Use this guide with the live Maternal and Pediatric Pharmacology R21 program record. Then compare NIH grants complete guide, NIH R01 R21 R03 K awards comparison, what is a NOFO, Healthcare Grants Complete Guide, and the Grantsights grant database.

October 2026 Source Check

As of October 10, 2026, PAR-25-111 is expired. On June 5, 2026, NICHD issued NOT-HD-26-003 (opens in a new tab), which added one more due date: July 6, 2026 for new, renewal, resubmission, and revision applications. The NOFO then expired July 7, 2026 instead of the original May 8, 2026. The companion R01, PAR-25-110, also expired July 7, 2026. Use this guide for reissue planning and route comparison, not as an open submission path.

The source was clinical trial optional, but institute limits matter. NIAID and NIDA did not support clinical trials under this announcement.

7 PAR-25-111 Eligibility Stop Checks

Within 21 days, use this section as the checkpoint for the maternal and pediatric R21 route before a team writes beyond the aims page.

7 stop checks decide whether this route fits.

Stop checkStrong R21 signalRed flag
PopulationPregnant, lactating, fetal, neonatal, pediatric, or adolescent focusGeneral adult pharmacology
TherapeuticsDrug action, safety, dosing, models, biomarkers, or treatment toolsNormal biology without therapeutic link
Translational pathDirect clinical or health impact is plausibleDiscovery-only aims
MechanismR21 scope can answer the questionFull R01-scale plan
Trial statusOptional, with institute-specific limitsTrial proposed under a non-supporting institute
Data sharingHuman data and biospecimen sharing plan is readyNo sharing path
Companion routeR01 comparison is doneMechanism picked by habit
Source statusExpired path is used for planning onlyTeam tries to submit to PAR-25-111
Institute limitNIAID and NIDA trial limits are checkedTrial plan assumes all ICs accept trials

5 Source Facts Applicants Should Know

Within 21 days, use this section as the checkpoint for the maternal and pediatric R21 route before a team writes beyond the aims page.

NIH lists PAR-25-111 as an R21 Exploratory/Developmental Research Grant, clinical trial optional, with companion R01 PAR-25-110.

FactSource-backed read
Funding numberPAR-25-111
MechanismR21 Exploratory/Developmental Research Grant
Clinical trial statusOptional
BudgetUp to $275,000 direct costs over 2 years
ExpirationJuly 7, 2026 (extended by NOT-HD-26-003)
Final new dateJuly 6, 2026
Final resubmission dateJuly 6, 2026
Companion routePAR-25-110 R01, also expired

According to USAspending.gov (opens in a new tab) data, the connected assistance listing (93.865) had about $1.24B in FY2024 obligations across 5,330 awards active that year.

What This Program Has Funded

Grantsights checked NIH RePORTER (opens in a new tab) on October 10, 2026. Under PAR-25-111, it lists 2 FY2026 awards: 1R21HD122283-01 to the Medical College of Wisconsin (NICHD, $418,000 total cost) for a bronchopulmonary dysplasia therapeutic strategy, and 1R21AI196618-01A1 to St. Jude Children's Research Hospital (NIAID, $335,871) on precision dosing of beta-lactam antibiotics in immunocompromised children. The St. Jude award was funded on resubmission.

The predecessor R21, PAR-23-131, gives a larger sample. RePORTER lists 9 new awards in FY2024 and FY2025, with first-year total costs from $189,056 to $477,406:

AwardOrganizationTopic
1R21HD119501-01University of FloridaBetamethasone dosing in twin pregnancy
1R21HD115866-01A1SUNY BinghamtonPBPK modeling for medication safety during lactation
1R21HD116421-01Children's Mercy Hospital, Kansas CityPhase I inhaled ciclesonide in preterm infants
1R21HD117135-01Penn StateMilk-protein drug delivery for hydrophobic APIs
1R21HD115076-01Neurosant Therapeutics LLCTherapeutics for Smith-Magenis syndrome

Grantsights analysis of these 11 awards shows two patterns. Most went to NICHD, with a few at NIAID. And funded topics were concrete therapeutic questions (a dose, a delivery form, a model that predicts exposure) rather than general maternal or child biology. A small business, Neurosant Therapeutics, also won an award, so for-profit applicants weren't shut out.

What Comes Next: The PAR-28-059 Forecast

NICHD posted a forecast on August 20, 2026 for PAR-28-059 (opens in a new tab), a renewal of this program. According to the Grants.gov forecast, NICHD intends to publish the NOFO under its Best Pharmaceuticals for Children Act and PRGLAC responsibilities. The estimated posting date is March 31, 2027, the estimated application due date is July 9, 2027, and estimated awards start April 1, 2028. The forecast doesn't name an activity code or award size, and it says applications aren't being solicited yet. Those dates are estimates, so check the posted NOFO before you build a calendar around them.

What NIH Doesn't Tell You

Within 21 days, use this section as the checkpoint for the maternal and pediatric R21 route before a team writes beyond the aims page.

4 practical issues decide whether this R21 is worth drafting.

First, maternal or pediatric labels are not enough. The application has to show a therapeutics question, such as precision dosing, safety prediction, placental transfer, pediatric ontogeny, therapeutic repurposing, biomarkers, or a clinical decision tool.

Second, an R21 is small. The $275,000 direct-cost cap means the team needs a narrow, high-yield proof point, not a full therapeutic development program.

Third, trial status depends on institute fit. The NOFO was clinical trial optional, but NIH notes that NIAID and NIDA did not support clinical trials for this announcement.

Fourth, expired status matters. Applicants need to know the route is closed and should use the guide for reissue monitoring or adjacent-route comparison.

6 Evidence Assets That Make This R21 Stronger

Within 21 days, use this section as the checkpoint for the maternal and pediatric R21 route before a team writes beyond the aims page.

6 evidence assets make the route stronger. The first is a clear population definition. Pregnant, postpartum, lactating, fetal, neonatal, pediatric, adolescent, and disability-related settings have different pharmacology issues.

The second is a therapeutic decision. A strong project can say what decision changes if the R21 succeeds.

The third is a model or tool readiness statement. This can include pharmacometric models, microphysiological systems, biomarkers, machine learning, drug safety methods, or clinical decision tools.

The fourth is a feasibility table. It should include data source, biospecimens, recruitment path if any, assay or model readiness, endpoints, safety issues, and sharing plan.

The fifth is an institute-fit memo. NICHD, NIAID, NIDA, and ORWH interests differ. The team should not assume the same trial plan fits every component.

The sixth is a next-route decision. The R21 should produce evidence that supports an R01, trial route, implementation study, or stop decision.

5 Route Choices Before Drafting

Within 21 days, use this section as the checkpoint for the maternal and pediatric R21 route before a team writes beyond the aims page.

5 routes should be compared before a team drafts.

RouteBetter first read when...Why
PAR-25-111 modelEarly translational therapeutics question fits R21 scopeThe route is purpose-built
PAR-25-110 R01Work needs larger scale or stronger preliminary dataCompanion R01 exists
Parent R21The specific PAR is closedActive route may be needed
Clinical trial routeA powered human intervention is centralR21 cap may be too small
Institute-specific NOFOPopulation or disease area is narrowerMission fit may improve

6 Bad-Fit Signals

Within 21 days, use this section as the checkpoint for the maternal and pediatric R21 route before a team writes beyond the aims page.

6 bad-fit signals should be visible. First, the project is mechanistic biology without a maternal or pediatric therapeutics question.

Second, the work does not address maternal or pediatric pharmacology. Third, the project needs a large trial or full product development. Fourth, the team has not resolved whether clinical-trial support fits the intended institute.

Fifth, the data or biospecimen sharing plan is vague. Sixth, the endpoint is not tied to therapeutic safety, effectiveness, dosing, or decision support.

21-Day R21 Routing Plan

Within 21 days, use this section as the checkpoint for the maternal and pediatric R21 route before a team writes beyond the aims page.

Days 1 through 3 should confirm source status, deadline, clinical-trial status, budget, and institute participation.

Days 4 through 7 should write the therapeutic decision statement: population, intervention or model, decision, and expected output.

Days 8 through 12 should build the feasibility table. Include data source, study population, model system, biomarker, endpoint, consent, biospecimen, and sharing needs.

Days 13 through 16 should compare the companion R01 and parent routes. If the project cannot fit the R21 cap, stop forcing it.

Days 17 through 21 should draft the program-staff memo and identify the required human-subjects or clinical-trial materials.

7 Above-the-Fold Claims That Need Proof

Within 21 days, the first screen should prove 7 claims: what the route funds, whether the source is open or expired, whether clinical trials are allowed, what budget rule applies, who is eligible in practice, what does not fit, and what route should be compared next.

According to NIH in the NOFO (opens in a new tab), this source should be treated as the authority for rules.

7 Route Checks Added June 2, 2026

Checked on June 2, 2026 against PAR-25-111 (opens in a new tab), PAR-25-110 (opens in a new tab), the Grants.gov listing (opens in a new tab), USASpending.gov (opens in a new tab), and USASpending.gov (opens in a new tab).

CheckPublic answer
EligibilityConfirm the applicant, institution, and route rules for PAR-25-111 maternal pediatric pharmacology R21 eligibility.
Source statusVerify the official listing, notices, due date, and expiration status.
BudgetCheck award size, cost limits, match, or budget logic when the source provides it.
EvidenceName the data, preliminary work, partner role, or implementation proof needed.
Bad fitStop if the project belongs in a nearby NIH or federal route.
Review criteriaTie the first page to significance, approach, team, environment, and source-specific criteria.
Next actionDecide whether to draft, ask a program contact, or redirect to a nearby route.

Final public checklist

  • Confirm whether R21 is the right route or whether a nearby program fits better.
  • Check budget, partner, match, or data-readiness constraints.

Sources

Largest awards active in FY2024

One row per recipient, its largest award | 5,330 Assistance Listing records | Avg: $2.8M

REAL DATA
1

Fred Hutchinson Cancer Center

WA

$1.1B
2

University of California, Los Angeles

CA

$996.1M

Use the visible recipient rows as free source context

This program has no reviewed paid report today.

No reviewed paid report is currently offered for this program. The visible source rows remain free.

Next steps

Where to go next

These next pages help you move from research into a specific grant choice.

Frequently Asked Questions

What does PAR-25-111 fund?

It supports R21 translational and clinical research on safe and effective therapeutics for pregnant women, lactating women, fetuses, neonates, children, and adolescents.

Are clinical trials allowed?

Yes. PAR-25-111 was clinical trial optional, but NIAID and NIDA did not support clinical trials under this announcement.

What budget applies?

NIH says direct costs may not exceed $275,000 over the two-year project period, with no more than $200,000 in any single year.

Is this opportunity still open?

No. NICHD extended PAR-25-111 by one due date in NOT-HD-26-003, so the last applications were due July 6, 2026 and the NOFO expired July 7, 2026. NICHD has forecast a renewal, PAR-28-059.

Who should skip this route?

Skip it if the project does not address maternal or pediatric pharmacology, or if the work is normal biology without a therapeutics connection.

Last updated October 10, 2026. Published by Grantsights from public sources. See our editorial policy, how we build and check guides, corrections and how we make money.